Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | TGM1 | P22735 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392184 | 0.96 | ALDH1A1 (0.49) | ALDH1A1CCR6PAX8F13A1TGM2 | |
| SCHEMBL392903 | 0.94 | ALDH1A1 (0.47) | ALDH1A1CCR6PAX8F13A1TGM2 | |
| SCHEMBL9684805 | 0.94 | ALDH1A1 (0.47) | ALDH1A1CCR6PAX8F13A1TGM2 | |
| SCHEMBL391715 | 0.91 | ALDH1A1 (0.53) | ALDH1A1CCR6PAX8F13A1TGM2 | |
| SCHEMBL393422 | 0.88 | HTT (0.52) | ALDH1A1CCR6PAX8F13A1TGM2 | |
| SCHEMBL16306384 | 0.86 | ALDH1A1 (0.46) | ALDH1A1CCR6PAX8F13A1TGM2 | |
| SCHEMBL1225570 | 0.85 | ALDH1A1 (0.49) | ALDH1A1CCR6PAX8F13A1TGM2 | |
| SCHEMBL7367495 | 0.85 | ALDH1A1 (0.58) | ALDH1A1CCR6PAX8F13A1TGM2 | |
| SCHEMBL389007 | 0.84 | HTT (0.51) | ALDH1A1CCR6PAX8F13A1TGM2 | |
| SCHEMBL1897393 | 0.84 | CCR6 (0.51) | ALDH1A1CCR6PAX8F13A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008062-B1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-04-05 | — | — | EP | disclosed |
| US-9586958-B2 | Prodrug derivatives of substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9586958-B2 | Prodrug derivatives of substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20160207915-A1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160207915-A1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| CN-105377848-A | Prodrug derivatives of substituted triazolopyridines | Bayer Pharma AG | 2016-03-02 | — | — | CN | disclosed |
| WO-2014198647-A2 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| US-8334284-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334284-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334284-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | BAYER HELTHCARE AG | 2011-02-10 | — | — | US | disclosed |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | BAYER HELTHCARE AG | 2011-02-10 | — | — | US | disclosed |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | BAYER HELTHCARE AG | 2011-02-10 | — | — | US | disclosed |
| CN-101730695-A | Aminoacyl prodrugs as an active pharmaceutical ingredient for thromboembolic disorders | BAYER HEALTHCARE AG | 2010-06-09 | — | — | CN | disclosed |
| EP-2167500-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayer Schering Pharma AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| CN-101384585-A | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER HEALTHCARE AG (DE) | 2009-03-11 | — | — | CN | disclosed |
| WO-2009007027-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007028-A1 | PRODRUG DERIVATIVES OF 1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXOPIPERIDIN-1-YL)PHENYL]-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINE-3-CARBOXAMIDE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007027-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007028-A1 | PRODRUG DERIVATIVES OF 1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXOPIPERIDIN-1-YL)PHENYL]-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINE-3-CARBOXAMIDE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207915-A1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | TK1, PNKP, MPST | ALDH1A1 2459/4885CCR6 3038/4885PAX8 4695/4885 |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | PLG, AADAC, DNPEP | ALDH1A1 1220/4885CCR6 4038/4885PAX8 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.